RICERCA ITALIANA     

FIRB simili:

• 1 - PROFILO GENOMICO DEI DISORDINI LINFOPROLIFERATIVI ACUTI E CRONICI DELL'UOMO PER LO SVILUPPO DI NUOVE PROPOSTE CLASSIFICATIVE, MARCATORI DI PROGNOSI E STRATEGIE TERAPEUTICHE INNOVATIVE.
• 2 - Identificazione ed analisi funzionale delle alterazioni molecolari e geniche che caratterizzano i tumori della mammella ormono-responsivi
• 3 - Identificazione di nuovi marcatori molecolari per la diagnosi e la prognosi del carcinoma renale con tecniche genomiche e proteomiche. (Possibile risultato atteso: Identificazione di nuovi marcatori diagnostici o prognostici di malattie).
• 4 - Sistemi di diagnostica molecolare per l'identificazione e l'analisi di determinanti genetici di rilevanza per l'agroindustria, la zootecnica e l'ambiente
• 5 - Il sistema di trasduzione del segnale Ca2+: dalle molecole alle funzioni
• 6 - Il riconoscimento molecolare nelle interazioni proteina-ligando, proteina-proteina e proteina superficie: sviluppo di approcci sperimentali e computazionali integrati per lo studio di sistemi di interesse farmaceutico
• 7 - Identificazione e validazione di meccanismi genetico-molecolari coinvolti nel trasporto tubulare renale del sodio nell'ipertensione e nelle sue complicanze d'organo.
• 8 - Sviluppo di metodologie innovative per l'identificazione e la sintesi di nuove molecole a scopo terapeutico: applicazioni nel campo della malattia di Alzheimer
• 9 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 10 - Profili di espressione genica nell'iniziazione e progressione tumorale: correlazione con indicatori prognostici e terapeutici

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • ONCOLOGIA MEDICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

Classificazione geografica

• Regione: Lazio

Bibliografia

1.Bernard OA, Berger R. Molecular basis of 11q23 rearrangement in hematopoietic malignant proliferations. Genes Chrom Cancer 1995; 13(2):75-85.
2.Burnett AK, Goldstone AH, Stevens RM, et al.. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998;351:700-8.
3.Burnett AK, Wheatley K, Langabeer S, et al. Outcome of acute myeloid leukemias affecting core binding factor subunits:The UK MRC experience. Blood 1997; 90:Suppl.1, 390a.
4.Cline MJ. The molecular basis of leukemia. N Engl J Med 1994;330(5):328-36.
5.Cuneo A., Ferrant A, Michaux Jl, et al. Cytogenetic profile of minimally differentiated acute myeloid leukemia: Correlation with clinicobiological findings. Blood.1995;85:3688-3694.
6.Diverio D, Rossi V, Avvisati G, et al.. Early detection of relapse by prospective RT-PCR analysis of the PML/RAR alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter BLOOD. 1998;92:784-789.
7.Falini B, Flenghi L, Fagioli M et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (Anti-PML). Blood 1997;90:4046-4053.
8.Gabert J. Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica. 1999;84:107-9.
9.Grande A, Montanari M, Manfredini R et al. A functionally active RAR alpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Cell death and differentiation. 2001; 8:70-82.
10.Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients enteredinto the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-33.
11.Lindblad-Toh K, Tanenbaum DM, Daly MJ et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000;18(9):1001-5.
12.Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
13.Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia BLOOD. 1999; 94:2225-2229.
14.Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278:1059-64.
15.Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and Idarubicin (AIDA) therapy. Blood 1997;90(3):1014-21.
16.Manfredini R, Trevisan F, Grande A et al. Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. CANCER RESEARCH. 1999;59:3803-3811.
17.Mastrangelo T, Modena P, Tornielli S, et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene. 2000: 3;19(33):3799-804.
18.Mei R, Galipeau PC, Prass C, et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res. 2000 Aug;10(8):1126-37.
19.Minucci S, Nervi C, Lo Coco F, et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias. Oncogene. 2001;20:3110-3115.
20.Mumms JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000 Dec 15;228(2):151-65.
21.Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996 Dec;10(12):1911-8.
22.Panagopoulos I, Mertens F, Domansky HA, et al. No EWS/FLI1fusion transcripts in giant-cell tumors of bone. Int J Cancer. 2001 Sep15;93(6):769-72.
23.Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001 Aug;31(4):362-72.
24.Rabbits TH. Chromosomal translocations in human cancer. Nature 1994;372:143.
25.Radich J, Thomson B: Advances in the detection of minimal residual disease. Curr Opinion in Hematology. 1997;4:242-247.
26.San Miguel JF, Martínez A, Macedo A, et al. Immunophenotyping investigation of Minimal Residual Disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90:2465-2470.
27.Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273:494-7.
28.Tamborini E, Agus V, Mezzelani A, et al. Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma. Br J Cancer. 2001 Apr 20;84(8):1087-94.
29.Tamborini E, Papini D, Mezzelani A,et al. c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases. Br J Cancer. 2001 Aug 3;85(3):405-11.
30.Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood. 2000;95:815-9.
31.Warrel RP Jr, de Thé H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177.
32.Whitman SP, Archer KJ, Feng L, et al. Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3: A Cancer and Leukemia Group B Study. Cancer Res.2001;61(19):7233-9.
33.Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001 Apr 15;97(8):2434-9.

Parole Chiave

leucemie mieloidi acute; sarcomi; caratterizzazione genetico-molecolare; profili di espressione genica; bioinformatica; anticorpi monoclonali